Some Myeloma Patients With del(17p) or t(4:14) Fare Better Than Others
Some Myeloma Patients With del(17p) or t(4:14) Fare Better Than Others image
Some Myeloma Patients With del(17p) or t(4:14) Fare Better Than Others
Posted Nov 02, 2015

Certain trisomies, when there are three instances of a particular chromosome instead of two, significantly improve overall survival in patients with multiple myeloma with del(17p) or t(4;14) genetic mutations, while the trisomy that causes Down's syndrome was found to worsen overall survival, a new study published online ahead of print in the journal Blood has shown. Although del(17p) and t(4;14) are the major abnormalities that drive poor outcomes in patients with multiple myeloma, the outcome of these high-risk patients is not always consistent. Some patients may display long survival. Therefore, researchers sought to identify concomitant “good risk” chromosomal changes that might improve outcomes in these patients. For the study, researchers analyzed data from 965 patients with multiple myeloma, including 168 with t(4;14) and 126 patients with del(17p). As hypothesized, researchers found that trisomic chromosomes were highly associated with survival. Results showed that trisomy 3 improved time to progression and trisomies 3 and/or 5 significantly improved overall survival in patients with multiple myeloma, while trisomy 21 worsened overall survival. The study demonstrated that in patients with t(4;14) especially, trisomies 3 and/or 5 appeared to overcome the poor prognosis in these high-risk patients. “This finding could be important for routine assessment of prognosis in myeloma, some high-risk patients with a traditional evaluation could be in fact standard risk,” the authors concluded. For the full article, visit Cancer Therapy Advisor.

The author Lizzy Smith

about the author
Lizzy Smith

Lizzy Smith was diagnosed with myeloma in 2012 at age 44. Within days, she left her job, ended her marriage, moved, and entered treatment. "To the extent I'm able, I want to prove that despite life's biggest challenges, it is possible to survive and come out stronger than ever," she says.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811